Welcome to the new version of CaltechAUTHORS. Login is currently restricted to library staff. If you notice any issues, please email coda@library.caltech.edu
Published February 15, 2019 | public
Journal Article Open

Semisynthesis of an Anticancer DPAGT1 Inhibitor from a Muraymycin Biosynthetic Intermediate


We have explored a method to convert a muraymycin biosynthetic intermediate 3 to an anticancer drug lead 2 for in vivo and thorough preclinical studies. Cu(OAc)₂ forms a stable complex with the amide 4 and prevents electrophilic reactions at the 2-((3-aminopropyl)amino)acetamide moiety. Under the present conditions, the desired 5″-primary amine was selectively protected with (Boc)₂O to yield 6. The intermediate 6 was converted to 2 in two steps with 90% yield.

Additional Information

© 2019 American Chemical Society. Received: November 20, 2018; Published: January 30, 2019. We thank the National Institutes of Health (Grant No. GM114611). M.K. also thanks the University of Tennessee Health Science Center for generous financial support (UTHSC College of Pharmacy, CORNET, and UTRF awards). NMR data were obtained on instruments supported by the NIH Shared Instrumentation Grant. Streptomyces sp. NRRL 30471 was acquired from USDA (NRRL Culture Collection). The authors declare no competing financial interest.

Attached Files

Accepted Version - nihms-1008789.pdf

Supplemental Material - ol8b03716_si_001.pdf


Files (4.7 MB)
Name Size Download all
3.8 MB Preview Download
928.7 kB Preview Download

Additional details

August 19, 2023
August 19, 2023